Borrower record · Q2 2026
Taysha Gene Therapies
As filed by 2 BDCs · period end 30 June 2026NAICS 31-33 · Manufacturing
Two lenders report $46.4m of Taysha Gene Therapies at Q2 2026, marked at 102.2 cents. The filed maturities run to September 2030.
- Filed fair value
- $46.4m
- 2 funded positions
- Reporting lenders
- 2
- across 2 filed positions
- Aggregate mark
- 102.2c
- cost filed on all 2 positions
- Maturities to
- 2030
- one date, 1 September 2030
- Periods on record
- 5
- first filed Q2 2025
How this total is counted
- Every figure above is the sum of 2 funded positions filed by 2 BDCs, each one cited below.
- Counted from the Q2 2026 filings imported for this build, the latest of them filed 20 August 2026. A schedule filed after that date is not in these figures and will appear when the property is rebuilt.
Pricing as filed
2 floating tranches · Prime / SOFR400bp on all 2 floating tranches — every filer reports the same spread.
Rate structure
Floating, on all 2 positions whose interest type a filer disclosed.
Maturity profile
all 2 funded positions dated2030
$46.4m
4.2 years to maturity, weighted by fair value across the 2 dated positions.
Credit flags
No lender reports this borrower on non-accrual, and no filed tranche pays in kind.
Not in the filings
- No period-by-period totals across the 5 periods on record. A single filer is separable somewhere in that history — at a period only one of them reported, or in the difference between two — so the series would give up that filer's position.
- No filed seniority on any of the 2 funded positions.
- No mark dispersion. Fewer than four filers disclosed a cost, so the distance between the highest and lowest mark would place each of them.
- No index floor filed on any tranche.
Sign up for free
Who holds it, and where they mark it.
2 lenders hold the same credit and mark it differently. Behind the gate, one row each — for this borrower and for every other one on this site, free and with no limit on how many you read.
LenderPositionsFair valueMarkSpreadMaturityAccrual
- The spread between the highest and lowest lender mark
- Quarter-on-quarter movement across 5 periods
- Peer comparison against borrowers with the same lenders
- The 10-Q or 10-K behind every row, by accession number
Every filing behind this page
2 filers · Q2 2026| Filer | CIK | Form | Period | Filed | Accession |
|---|---|---|---|---|---|
| Eagle Point Trinity Senior Secured Lending Co | 0002027033 | 10-Q | 2026-06-30 | 2026-08-14 | 0002027033-26-000011 |
| Trinity Capital Inc. (TRIN) | 0001786108 | 10-Q | 2026-06-30 | 2026-08-05 | 0001193125-26-333907 |
Related borrowers
Same lenders
Tilt Finance2 shared lenders · $117.2m filedRarefied Atmosphere2 shared lenders · $64.1m filedCellares2 shared lenders · $53.4m filedTogether Computer2 shared lenders · $51.2m filedAngel Studios2 shared lenders · $49.2m filedVital Connect2 shared lenders · $48.1m filed
Same sector
Candel TherapeuticsSame sector · $46.5m filedBridges Consumer Healthcare IntermediateSame sector · $46.8m filedDr. Scholls DRS Holdings IIISame sector · $44.5m filedCobalt Buyer SubSame sector · $49.3m filedRoC Skincare RoC HoldcoSame sector · $49.5m filedNMC Skincare Intermediate Holdings IISame sector · $43.1m filed